79 related articles for article (PubMed ID: 16979746)
1. Strong significant correlation between MMP-9 and systemic symptoms in patients with localized renal cell carcinoma.
Kawata N; Nagane Y; Igarashi T; Hirakata H; Ichinose T; Hachiya T; Takimoto Y; Takahashi S
Urology; 2006 Sep; 68(3):523-7. PubMed ID: 16979746
[TBL] [Abstract][Full Text] [Related]
2. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
[TBL] [Abstract][Full Text] [Related]
3. How do symptoms have an impact on the prognosis of renal cell carcinoma?
Kawata N; Nagane Y; Yamaguchi K; Ichinose T; Hirakata H; Takahashi S
Int J Urol; 2008 Apr; 15(4):299-303. PubMed ID: 18380815
[TBL] [Abstract][Full Text] [Related]
4. Expression of matrix metalloproteinase-7 on cancer cells and tissue endothelial cells in renal cell carcinoma: prognostic implications and clinical significance for invasion and metastasis.
Miyata Y; Iwata T; Ohba K; Kanda S; Nishikido M; Kanetake H
Clin Cancer Res; 2006 Dec; 12(23):6998-7003. PubMed ID: 17145820
[TBL] [Abstract][Full Text] [Related]
5. Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis.
de Vicente JC; Lequerica-Fernández P; Santamaría J; Fresno MF
J Oral Pathol Med; 2007 Aug; 36(7):415-24. PubMed ID: 17617835
[TBL] [Abstract][Full Text] [Related]
6. Expression of nm23-H1 gene product in sarcomatous cancer cells of renal cell carcinoma: correlation with tumor stage and expression of matrix metalloproteinase-2, matrix metalloproteinase-9, sialyl Lewis X, and c-erbB-2.
Ohba K; Miyata Y; Koga S; Kanda S; Kanetake H
Urology; 2005 May; 65(5):1029-34. PubMed ID: 15882758
[TBL] [Abstract][Full Text] [Related]
7. Clinical symptoms in localized renal cell carcinoma reflect its invasive potential: comparative study between incidentally detected and symptomatic diseases.
Harada K; Sakai I; Ishimura T; Inoue TA; Hara I; Miyake H
Urol Oncol; 2006; 24(3):201-6. PubMed ID: 16678049
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.
Pennanen H; Kuittinen O; Soini Y; Turpeenniemi-Hujanen T
Eur J Haematol; 2008 Oct; 81(4):289-97. PubMed ID: 18616513
[TBL] [Abstract][Full Text] [Related]
9. Expression of matrix metalloproteinase-10 in renal cell carcinoma and its prognostic role.
Miyata Y; Iwata T; Maruta S; Kanda S; Nishikido M; Koga S; Kanetake H
Eur Urol; 2007 Sep; 52(3):791-7. PubMed ID: 17207914
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples.
Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R
Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785
[TBL] [Abstract][Full Text] [Related]
11. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase activity in urine of patients with renal cell carcinoma leads to degradation of extracellular matrix proteins: possible use as a screening assay.
Sherief MH; Low SH; Miura M; Kudo N; Novick AC; Weimbs T
J Urol; 2003 Apr; 169(4):1530-4. PubMed ID: 12629409
[TBL] [Abstract][Full Text] [Related]
13. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
Unsal D; Akyurek N; Uner A; Erpolat OP; Han U; Akmansu M; Mentes BB; Dursun A
Am J Clin Oncol; 2008 Feb; 31(1):55-63. PubMed ID: 18376229
[TBL] [Abstract][Full Text] [Related]
14. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
[TBL] [Abstract][Full Text] [Related]
15. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer.
Iniesta P; Morán A; De Juan C; Gómez A; Hernando F; García-Aranda C; Frías C; Díaz-López A; Rodríguez-Jiménez FJ; Balibrea JL; Benito M
Oncol Rep; 2007 Jan; 17(1):217-23. PubMed ID: 17143501
[TBL] [Abstract][Full Text] [Related]
16. Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas.
Ramankulov A; Lein M; Johannsen M; Schrader M; Miller K; Jung K
Cancer Sci; 2008 Jun; 99(6):1188-94. PubMed ID: 18422740
[TBL] [Abstract][Full Text] [Related]
17. [mRNA expression analysis of metastatic markers in clear-cell renal cell carcinoma].
Struckmann K; Mertz K; Staller P; Krek W; Schraml P; Moch H
Verh Dtsch Ges Pathol; 2005; 89():178-83. PubMed ID: 18035688
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
Eissa S; Ali-Labib R; Swellam M; Bassiony M; Tash F; El-Zayat TM
Eur Urol; 2007 Nov; 52(5):1388-96. PubMed ID: 17466450
[TBL] [Abstract][Full Text] [Related]
19. Ratio of metalloproteinase 2 to tissue inhibitor of metalloproteinase 2 in medullary thyroid carcinoma.
Cavalheiro BG; Junqueira CR; Brandão LG
Arch Otolaryngol Head Neck Surg; 2009 Aug; 135(8):812-7. PubMed ID: 19687404
[TBL] [Abstract][Full Text] [Related]
20. Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer.
Vasala K; Turpeenniemi-Hujanen T
Clin Biochem; 2007 Jun; 40(9-10):640-4. PubMed ID: 17374529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
